FACTORS CONTRIBUTING TO THE ACHIEVEMENT OF REMISSION AND DEVELOPMENT OF EXACERBATIONS IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS WITH NO SYSTEMIC MANIFESTATIONS, RECEIVING THERAPY WITH ADALIMUMAB


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

The article presents the results of evaluation of the efficacy and safety of adalimumab in 53 children with juvenile idiopathic arthritis without systemic manifestations, as well as the evaluation of the timing and the possibility of reaching of inactive disease, the frequency of exacerbations, as well as their causes and side effects.

Texto integral

Acesso é fechado

Sobre autores

M. Kostik

SBEI HPE "Saint Petersburg State Pediatric Medical University" of RMH

Email: kost-mikhail@yandex.ru
PhD, Associate Professor at the Department of Hospital Pediatrics St. Petersburg

M. Dubko

SBEI HPE "Saint Petersburg State Pediatric Medical University" of RMH

St. Petersburg

E. Isupova

SBEI HPE "Saint Petersburg State Pediatric Medical University" of RMH

St. Petersburg

I. Chikova

SBEI HPE "Saint Petersburg State Pediatric Medical University" of RMH

St. Petersburg

E. Gaydar

SBEI HPE "Saint Petersburg State Pediatric Medical University" of RMH

St. Petersburg

V. Masalova

SBEI HPE "Saint Petersburg State Pediatric Medical University" of RMH

St. Petersburg

L. Snegireva

SBEI HPE "Saint Petersburg State Pediatric Medical University" of RMH

St. Petersburg

O. Kalashnikova

SBEI HPE "Saint Petersburg State Pediatric Medical University" of RMH

St. Petersburg

V. Chasnyk

SBEI HPE "Saint Petersburg State Pediatric Medical University" of RMH

St. Petersburg

Bibliografia

  1. Ravelli A., Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369:767-78.
  2. Petty R.E., Southwood T.R., Manners P., Baum J., Glass D.N., Goldenberg J., He X., Maldonado-Cocco J, Orozco-Alcala J., Prieur A.M., Suarez-Almazor M.E., Woo P. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton 2001. J. Rheumatol. 2004;31:390-92.
  3. Cassidy J., Petty R., Laxer R.M., Lindsley C.B. Textbook of Pediatric Rheumatology. 6th ed. Elsevier. 2011. 794 p.
  4. Beukelman T., Patkar N.M., Saag K.G., Tolleson- Rinehart S., Cron R.Q., DeWitt E.M., Ilowite N.T., Kimura Y., Laxer R.M., Lovell D.J., Martini A., Rabinovich C.E., Ruperto N. 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Initiation and Safety Monitoring of Therapeutic Agents for the Treatment of Arthritis and Systemic Features. Arthritis Care & Research. 2011;63(4):465-82.
  5. Бзарова Т.М. Ингибиторы фактора некроза опухоли альфа в лечении ювенильного идиопатического артрита. Дисс. докт. мед. наук. М., 2015.
  6. Wallace C.A, Ruperto N., Giannini E.H. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J. Rheumatol. 2004;31:2290-94.
  7. Cassidy J., Kivlin J., Lindsley C., Nocton J. The Section on Rheumatology, and the Section on Ophthalmology. Ophthalmic examinations in children with juvenile rheumatoid arthritis. Pediatrics. 2006;117:1843-45.
  8. Lovell D.J., Ruperto N., Goodman S., Reiff A., Jung L., Jarosova K., Nemcova D., Mouy R., Sandborg C., Bohnsack J., Elewaut D., Foeldvari I., Gerloni V., Rovensky J., Minden K., Vehe R.K., Weiner L. W., Horneff G.,Huppertz H.I., Olson N. Y., Medich J.R., Carcereri-De-Prati R., McIlraith M.J., Giannini E.H., Martini A; Pediatric Rheumatology Collaborative Study Group; Pediatric Rheumatology International Trials Organisation. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N. Engl. J. Med. 2008;359(8):810-20.
  9. Lovell D.J., Giannini E.H., Reiff A., Cawkwell G.D., Silverman E.D, Nocton J.J., Stein L.D., Gedalia A., Ilowite N.T., Wallace C.A., Whitmore J., Finck B.K. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N. Engl. J. Med. 2000;342(11):763-69.
  10. Imagawa T., Takei S., Umebayashi H., Yamaguchi K., Itoh Y., Kawai T., Iwata N., Murata T., Okafuji I., Miyoshi M., Onoe Y., Kawano Y., Kinjo N., Mori M., Mozaffarian N., Kupper H., Santra S., Patel G., Kawai S., Yokota S. Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan. Clin. Rheumatol. 2012;31(12):1713-21.
  11. Guzman J.,Oen K.,Tucker L.B.,Huber A.M.,Shiff N., Boire G., Scuccimarri R., Berard R., Tse S.M., Morishita K., Stringer E., Johnson N., Levy D.M., Duffy K.W., Cabral D.A., Rosenberg A.M., Larche M., Dancey P., Petty R.E., Laxer R.M., Silverman E., Miettunen P., Chetaille A.L., Haddad E., Houghton K., Spiegel L., Turvey S.E., Schmeling H., Lang B., Ellsworth J., Ramsey S., Bruns A., Campillo S., Benseler S., Chedeville G., Schneider R.,Yeung R., Duffy C.M; ReACCh-Out investigators. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Ann. Rheum. Dis. 2015;74(10): 1854-60.
  12. Burgos-Vargas R., Tse S.M., Horneff G., Pangan A.L., Kalabic J., Goss S., Unnebrink K., Anderson J.K. A Randomized, Double Blind, Placebo-Controlled Multicenter Study of Adalimumab in Pediatric Patients With Enthesitis-Related Arthritis. Arthritis Care Res. (Hoboken). 2015;67(11):1503-12.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2016

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies